Chinas 2013 Life Sciences Industry Outlook and Regulatory Review

Government Investments Could Make China the Third-largest Pharmaceutical Market in the World

Regular Price: USD 4,950

Special Price USD 4,208

15% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,208

PAY BY INVOICE

Be the first to review this product

China is predicted to become the third-largest pharmaceutical market in the world by the end of 2013 due to the government’s considerable investment in the healthcare industry and the population’s unmet healthcare needs. The life sciences industry is broad and involves a wide range of disciplines. This research service focuses on the trends and market opportunities in China’s life sciences industry—the regulatory environment, the registration pathway of various drugs and IVD products, and M&A. Medical devices and the related registration pathway are not included. In this study, the base year is 2012, and the forecast period runs 2013–2017. An analysis of market challenges, drivers, and restraints impacting industry growth are provided.

Table of Contents

China’s 2013 Life Sciences Industry Outlook and Regulatory Review , Analysis of China's Life Sciences Market Outlook and Regulatory Review, 2013 Analysis of China's Life Sciences Market Outlook and Regulatory Review, 2013Overview




Related Research

Release Date : 15-Sep-17

Region : Global

Release Date : 14-Sep-17

Region : Global

Release Date : 11-Sep-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.